TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3904436

Group type: EXPERIMENTAL
Intervention: Isoxicam at a dosage greater than 200 mg per day
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Isoxicam at 200 mg per day
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Buffered aspirin at 3,600 to 4,800 mg per day
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Indomethacin at 150 mg per day
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Buffered aspirin
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Isoxicam
Number of subjects: 1800
Study: 31166081

Group type: EXPERIMENTAL
Intervention: Fasudil 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasudil 30 mg
Number of subjects: 60
Study: 30307816

Group type: EXPERIMENTAL
Intervention: Aqueous solution containing betaine, zinc and polyhexamethylene biguanide (polihexanide)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 3% saline solution containing 0.2% sodium hypochlorite
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Irrigation solution containing sea salt 1.2% and NaOCl 0.4%
Number of subjects: 260

Group type: COMPARATOR
Intervention: Sterile 0.9% saline
Number of subjects: 260
Study: 28195010

Group type: EXPERIMENTAL
Intervention: Universal smoking cessation intervention (brief motivational interview and self-help material during hospitalization, followed by a 4-month pharmacological and psychosocial intervention post-discharge)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Universal smoking cessation intervention
Number of subjects: 754

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 754
Study: 24382109

Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behaviour Therapy for Psychosis (CaCBTp)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 42
Study: 24279026

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation technology (group A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Electric knife (group B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Scalpel (group C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (group D, control)
Number of subjects: 8
Study: 21262590

Group type: EXPERIMENTAL
Intervention: Continuous administration of combined oral estroprogestins (CON)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cyclic administration of combined oral estroprogestins (CYC)
Number of subjects: 57
Study: 18500097

Group type: EXPERIMENTAL
Intervention: Wavefront-optimized LASIK
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 374
Study: 16488356

Group type: EXPERIMENTAL
Intervention: RCT (Systolic Hypertension in Europe trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GPRD study (simulated Systolic Hypertension in Europe trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended GPRD study
Number of subjects: 0
Study: 12698853

Group type: EXPERIMENTAL
Intervention: Doxocycline (DC) 200 mg/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Erythromycin (EM) 2 g/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CF) 1 g/day
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CT) 1920 mg/day
Number of subjects: 79
Study: 11132912

Group type: EXPERIMENTAL
Intervention: TrocDoc
Number of subjects: 62

Group type: COMPARATOR
Intervention: Veress needle/first trocar
Number of subjects: 62

Group type: COMPARATOR
Intervention: Hasson trocar
Number of subjects: 62
Study: 9080151

Group type: EXPERIMENTAL
Intervention: External high-frequency oscillation ventilation for 4 hours, then positive pressure ventilation for 1 hour
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation throughout the observation period (5 hours)
Number of subjects: 24
Study: 8365932

Group type: EXPERIMENTAL
Intervention: 27 Gy hepatic irradiation
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 30 Gy hepatic irradiation
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 33 Gy hepatic irradiation
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Progressively higher total doses of hepatic irradiation
Number of subjects: 173
Study: 3521717

Group type: EXPERIMENTAL
Intervention: Acyclovir tablets (400 mg) administered five times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acyclovir ophthalmic ointment administered five times daily
Number of subjects: 60
Study: 29423520

Group type: EXPERIMENTAL
Intervention: CT-RT (Cisplatin Chemoradiotherapy)
Number of subjects: 850

Group type: COMPARATOR
Intervention: RT (Radiotherapy)
Number of subjects: 850
Study: 27500338

Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350 (PEG3350)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo (inert)
Number of subjects: 145
Study: 24646311

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: GAD autoantibody positivity
Number of subjects: 3050

Group type: EXPERIMENTAL
Intervention: Insulinoma‐associated‐2 autoantibodies
Number of subjects: 3050
Study: 23262213

Group type: EXPERIMENTAL
Intervention: Community-based biosecurity intervention involving community education and hygiene practices.
Number of subjects: 749
Study: 22039251

Group type: EXPERIMENTAL
Intervention: Revised grading criteria using annual stereoscopic color fundus photographs and fluorescein angiograms
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Use of two imaging modalities (color photographs and fluorescein angiograms)
Number of subjects: 114
Study: 18481719

Group type: EXPERIMENTAL
Intervention: Auricular point sticking combined with Tongshiji treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Simple Tongshiji treatment (control group)
Number of subjects: 300
Study: 16549945

Group type: EXPERIMENTAL
Intervention: EBC collection without a nose clip
Number of subjects: 40

Group type: COMPARATOR
Intervention: EBC collection with a nose clip
Number of subjects: 40
Study: 12624851

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 36
Study: 10745287

Group type: EXPERIMENTAL
Intervention: Diet counselling on protein restriction for 12 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual dietary advice (control group)
Number of subjects: 125
Study: 9185751

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (no EVL)
Number of subjects: 126
Study: 1587377

Group type: EXPERIMENTAL
Intervention: Immunotherapy utilizing the husband's lymphocytes
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Immunosuppressant and anticoagulant therapy
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Genetic counseling and ideal metroplasty
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Immunotherapy indicated but not received
Number of subjects: 1120
Study: 2876719

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion (0.4 to 0.5 micrograms kg‐1 min‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pethidine infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 30
Study: 31554490

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 37
Study: 29523108

Group type: EXPERIMENTAL
Intervention: Direct mailing of a second reminder and a self-sampling kit
Number of subjects: 9791

Group type: EXPERIMENTAL
Intervention: Mailing of a second reminder that offered a self-sampling kit to be ordered by e-mail, text message, phone, or webpage
Number of subjects: 9791

Group type: COMPARATOR
Intervention: Mailing of a second reminder to attend regular cytology screening
Number of subjects: 9791
Study: 26558600

Group type: EXPERIMENTAL
Intervention: Quality Protein Maize (QPM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 61
Study: 24139824

Group type: EXPERIMENTAL
Intervention: CaD (700 mg calcium + 200 IU vitamin D)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: CaDEA (700 mg calcium + 200 IU vitamin D + 12 IU vitamin E + 2,000 IU vitamin A)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Ca (700 mg calcium)
Number of subjects: 176
Study: 22420668

Group type: EXPERIMENTAL
Intervention: Real-time PCR assay
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Method C (including episodes of possible IFI as true positive)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 100
Study: 20015056

Group type: EXPERIMENTAL
Intervention: Methotrexate/NBUVB phototherapy (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo/NBUVB phototherapy (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17888202

Group type: EXPERIMENTAL
Intervention: Selenate (300 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (300 microg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium-enriched milk (480 microg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All selenium sources
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organic forms (Se-enriched yeast and Se-enriched milk)
Number of subjects: 0
Study: 19616498

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), three doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), two doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), one dose
Number of subjects: 0
Study: 15791443

Group type: EXPERIMENTAL
Intervention: 99mTc‐granulocytes (approximately 200 MBq) and 111In‐granulocytes (approximately 0.5 MBq)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whole-body 111In retention (WBR)
Number of subjects: 30
Study: 11480806

Group type: EXPERIMENTAL
Intervention: Definite/Etch & Prime 3.0 (D‐EP)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Solitaire/Solid Bond (S‐SB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both materials (D‐EP and S‐SB)
Number of subjects: 52
Study: 9497213

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation therapy (EVL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Endoscopic injection variceal sclerotherapy (EVS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Combination of EVL plus low-dose EVS
Number of subjects: 59
Study: 7961545

Group type: COMPARATOR
Intervention: Venlafaxine (75 to 375 mg/day)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Venlafaxine (higher dosages)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Venlafaxine (200 mg/day)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Venlafaxine (201-300 mg/day)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Venlafaxine (> 300 mg/day)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 3054555

Group type: EXPERIMENTAL
Intervention: Prophylactic transfusions of frozen red cells
Number of subjects: 72

Group type: COMPARATOR
Intervention: Red-cell transfusions only for medical or obstetric emergencies
Number of subjects: 72
Study: 31755939

Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor VIII activity
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor VIII antigen
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor XI activity
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Increased gamma (γ') fibrinogen
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Elevated plateletcrit
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Eosinophil percentage of white cells
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Thrombin‐activatable fibrinolysis inhibitor activation peptide antigen
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Genetically lower levels of factor XI
Number of subjects: 375000

Group type: EXPERIMENTAL
Intervention: Factor VIII and γ' fibrinogen
Number of subjects: 375000
Study: 31018869

Group type: EXPERIMENTAL
Intervention: Footwear intervention (podiatric care and gout education plus a commercially available athletic shoe)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (podiatric care and gout education)
Number of subjects: 94
Study: 29726748

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 112
Study: 26844011

Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 181
Study: 24558998

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study: 21793899

Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine lubricant eye drops
Number of subjects: 161000000

Group type: EXPERIMENTAL
Intervention: Systemic administration of carcinine
Number of subjects: 161000000

Group type: EXPERIMENTAL
Intervention: Parabulbar, subconjunctival, and intravitreal injection of carcinine
Number of subjects: 161000000
Study: 20642550

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily) and Itraconazole (200 mg once daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 17451383

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution twice daily for 12 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: 0.025% alfatradiol solution once daily for 6 months, then 2% minoxidil for months 7-12
Number of subjects: 103
Study: 15920714

Group type: EXPERIMENTAL
Intervention: Health advocacy, counselling, and activation programme
Number of subjects: 222

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 222
Study: 11788553

Group type: EXPERIMENTAL
Intervention: Barrett's oesophagus patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 23
Study: 10422856

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (unoperated contralateral eyes)
Number of subjects: 32
Study: 7583900

Group type: EXPERIMENTAL
Intervention: Intra-articular buprenorphine (0.30 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 1973585

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7367820

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Barium meal
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Parallel use of endoscopy and barium meal
Number of subjects: 173

Group type: COMPARATOR
Intervention: Routine use of barium meal with selective use of endoscopy
Number of subjects: 173

Group type: COMPARATOR
Intervention: X-ray examination
Number of subjects: 173
Study: 31804424

Group type: EXPERIMENTAL
Intervention: NTS group (n = 12) performing 3 screen‐based scenarios designed to train nontechnical skills (NTS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12) performing 3 basic scenarios of the screen‐based simulation without NTS training
Number of subjects: 24
Study: 27800628

Group type: EXPERIMENTAL
Intervention: Male gaze (objectifying gaze)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Female gaze (non-objectifying gaze)
Number of subjects: 107
Study: 26501782

Group type: EXPERIMENTAL
Intervention: Standard of care plus nutritional supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NAT2 genotype (slow vs rapid/intermediate)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time on treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 100
Study: 22818804

Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction (OHI) only
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OHI and 0.2% chlorhexidine mouth rinse twice daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OHI, 0.2% chlorhexidine mouth rinse twice daily, and assisted brushing twice weekly
Number of subjects: 102
Study: 20922564

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg IV, every 6 months
Number of subjects: 112

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 112
Study: 19389420

Group type: EXPERIMENTAL
Intervention: Computerised prevention program (Climate Schools: Alcohol and Cannabis prevention course)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Usual health classes
Number of subjects: 764
Study: 17530360

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus 15 mg/kg per day of ribavirin (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus ribavirin plus 200 mg/day of amantadine (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75
Study: 15253781

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard transperitoneal laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard retroperitoneal laparoscopic surgery
Number of subjects: 0
Study: 12588054

Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy (102 subjects)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Diet alone (154 subjects)
Number of subjects: 256
Study: 9648992

Group type: EXPERIMENTAL
Intervention: Serum zinc concentration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase activity
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Zinc in blood cells
Number of subjects: 31
Study: 8153377

Group type: EXPERIMENTAL
Intervention: CHART radiotherapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Conventional fractionated treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Both CHART and conventional treatment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Parotid glands
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Early changes in salivary gland function
Number of subjects: 47
Study: 2537340

Group type: EXPERIMENTAL
Intervention: 10 mg clomipramine (CMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg clomipramine (CMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 135853

Group type: EXPERIMENTAL
Intervention: Fast rehabilitation for patients with mild and moderate course of the disease
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Slower rehabilitation for patients with severe lesions
Number of subjects: 305
Study: 31266858

Group type: EXPERIMENTAL
Intervention: RACE score ≥5, taken to an endovascular capable center (ECC) as RACE-alerts (RA)
Number of subjects: 1639

Group type: COMPARATOR
Intervention: RACE score <5, taken to the nearest hospital as stroke-alerts (SA)
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: RACE score ≥5
Number of subjects: 1639

Group type: COMPARATOR
Intervention: RACE score <5
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: RACE-alerts (RA) with MT
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Stroke-alerts (SA) with MT
Number of subjects: 1639
Study: 31801135

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (420 IU per day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 27836356

Group type: EXPERIMENTAL
Intervention: Senna (maximum daily dose of 38.7mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Polyethylene glycol (17g)
Number of subjects: 28
Study: 25357149

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (1 hr/day, three times/week for 16 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 23394705

Group type: EXPERIMENTAL
Intervention: Busulfan plus fludarabine (BuFlu)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 108
Study: 22112329

Group type: EXPERIMENTAL
Intervention: Active management using synthetic oxytocin
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Both active and expectant management
Number of subjects: 1802
Study: 19167188

Group type: EXPERIMENTAL
Intervention: 1% cetrimide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Povidon‐iodine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 120
Study: 18402129

Group type: EXPERIMENTAL
Intervention: Lichtenstein herniorrhaphy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shouldice herniorrhaphy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Lichtenstein and Shouldice)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nerve graft contact
Number of subjects: 100
Study: 14988614

Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban infusion
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 119
Study: 11863317

Group type: EXPERIMENTAL
Intervention: Hirudin-containing cream (Hirudex cream; Hirudo medicinalis extract 280 UI/100 g) applied 3-4 times daily for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60